Watson Pharmaceuticals acquires Actavis Group

Watson Pharmaceuticals has completed its 4.25 billion Euro acquisition of Swiss competitor Actavis Group, making Watson the third-largest generic drug company worldwide. BDK advised Watson on their acquisition of Actavis’ Serbian subsidiary. BDK’s team was led by partner Vladimir Dasic.

Cart Item Removed. Undo
  • No products in the cart.